J-147

Sinonimi: J147, (E)-N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N’-[(E)-3-methoxybenzylidene]acetohydrazide, J-147, J 147, CAS 1146963-51-0

J-147 is a synthetic small molecule that emerged from a drug discovery program aimed at identifying compounds with broad neuroprotective and anti-aging properties. Unlike many experimental agents that target a single pathway, J-147 was designed to modulate multiple cellular processes associated with cognitive decline and neurodegeneration. Its structure incorporates a trifluoromethyl group and a methoxybenzylidene hydrazide moiety, which contribute to its metabolic stability and ability to cross the blood-brain barrier. Since its initial description in the scientific literature, J-147 has become a valuable tool compound for researchers investigating Alzheimer’s disease, Parkinson’s disease, and other age-related neurological conditions.

At the molecular level, J-147 acts through several distinct mechanisms. It has been shown to inhibit monoamine oxidase B (MAO-B), reduce oxidative stress, and enhance the production of brain-derived neurotrophic factor (BDNF). Additionally, J-147 modulates mitochondrial function and ATP levels, which are critical for neuronal survival. In preclinical studies, J-147 demonstrated the ability to improve memory and learning in various animal models, including those with amyloid-beta plaques and tau tangles. Its broad-spectrum activity sets it apart from many single-target neuroprotective agents, making it a subject of ongoing research interest.

J-147 is typically available as a high-purity crystalline solid, standardized to ≥98% by HPLC. It is primarily used in research settings for in vitro and in vivo studies exploring neuroprotection, cognitive enhancement, and anti-aging interventions. The compound is also investigated for its potential in treating traumatic brain injury and other neurodegenerative disorders. Due to its lipophilic nature, J-147 is often dissolved in DMSO or other organic solvents for experimental use. Its stability and bioavailability profile make it a preferred candidate for preclinical trials.

Funzione

• Neuroprotection: J-147 protects neurons from oxidative stress and excitotoxicity, supporting cell survival in models of neurodegeneration.
• MAO-B inhibition: It inhibits monoamine oxidase B, reducing the breakdown of dopamine and potentially alleviating motor symptoms in Parkinson’s disease.
• BDNF induction: J-147 increases brain-derived neurotrophic factor levels, promoting synaptic plasticity and cognitive function.
• Mitochondrial support: The compound enhances mitochondrial respiration and ATP production, improving energy metabolism in neurons.
• Anti-aging effects: In preclinical studies, J-147 has been associated with extended lifespan and improved healthspan in animal models.

Fonte e standardizzazione

• Fonte: Synthetic chemical synthesis
• Synthesis: Multi-step organic synthesis, followed by purification and crystallization
• Standardizzazione: ≥98.0% by HPLC
• Moduli: White to off-white crystalline powder
• Applicazioni: Research on Alzheimer’s disease, Parkinson’s disease, neuroprotection, and aging

Caratteristiche tecniche

Documentazione e forniture

• Capacità mensile: 50 kg
• Tempi di consegna: 3-5 business days (stock items)
• Documentazione: COA, MSDS, TDS available upon request
• Confezionamento: 10 mg, 50 mg, 100 mg, 500 mg, 1 g in amber glass vials; custom packaging available

Richiesta di preventivo

• LyvBio S.r.l. — E-mail: info@lyvbio.com